Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy

Recent studies suggest that thiazolidinediones ameliorate diabetic nephropathy (DN) independently of their effect on hyperglycemia. In the current study, we confirm and extend these findings by showing that rosiglitazone treatment prevented the development of DN and reversed multiple markers of oxid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhang, Hongyu, Saha, Jharna, Byun, Jaeman, Schin, MaryLee, Lorenz, Matthew, Kennedy, Robert T., Kretzler, Matthias, Feldman, Eva L., Pennathur, Subramaniam, Brosius, Frank C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Physiological Society 2008
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2576144/
https://ncbi.nlm.nih.gov/pubmed/18667486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.90208.2008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares